Skip to main content
. 2018 Mar 24;310(6):475–483. doi: 10.1007/s00403-018-1825-9

Fig. 1.

Fig. 1

Percentages of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75; primary endpoint) at week 16 in the head-to-head DMF/FAE mixture comparator study [32]. Results are also shown for the secondary endpoints of 50% improvement (PASI 50) and 90% improvement (PASI 90). *p < 0.001 vs. placebo; **p < 0.0001 vs. placebo; p < 0.001 for noninferiority vs. Fumaderm.

(Adapted from Mrowietz et al. [32])